sábado, outubro 21, 2006
Competição para Norvir?
Merck & Co announced last week that it has licensed an experimental protease inhibitor that does not require ritonavir boosting and which may be active against highly drug-resistant HIV. The compound, PPL-100, was developed by Ambrilia Biopharma (formerly Procyon) and previously by Pharmacor, both Montreal-based companies. PPL-100 appears to be just as potent a booster of other HIV protease inhibitors as ritonavir (Norvir).